Cargando…

Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study

PURPOSE: To correlate somatostatin receptor (SSTR) and proliferative activity profile (SSTR2, SSTR5, Ki-67) at immunohistochemistry (IHC) with SSTR-PET/CT imaging features in a retrospective series of lung neuroendocrine tumors (NET). Proliferative activity by Ki-67 and (18)F-FDG-PET/CT parameters (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rufini, Vittoria, Lorusso, Margherita, Inzani, Frediano, Pasciuto, Tina, Triumbari, Elizabeth Katherine Anna, Grillo, Lucia Rosalba, Locco, Filippo, Margaritora, Stefano, Pescarmona, Edoardo, Rindi, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525360/ https://www.ncbi.nlm.nih.gov/pubmed/35674739 http://dx.doi.org/10.1007/s00259-022-05848-z

Ejemplares similares

Correction to: Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study
por: Rufini, Vittoria, et al.
Publicado: (2022)

Introduction to neuroendocrine neoplasms of the digestive system: definition and classification
por: Inzani, Frediano, et al.
Publicado: (2021)

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
por: Morland, David, et al.
Publicado: (2023)

Diagnostic performance of preoperative [(18)F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study
por: Rufini, Vittoria, et al.
Publicado: (2021)

THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
por: Raia, Salvatore, et al.
Publicado: (2023)

Risk factors for pancreas and lung neuroendocrine neoplasms: a case–control study
por: Giraldi, Luca, et al.
Publicado: (2020)

(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study
por: Taralli, Silvia, et al.
Publicado: (2018)

Long Axial Field-of-View PET/CT Could Answer Unmet Needs in Gynecological Cancers
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2023)

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors
por: Helgebostad, Rasmus, et al.
Publicado: (2022)

Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic and Immunohistochemical Study with Focus on Novel Markers (Sst2–Sst5)
por: Inzani, Frediano, et al.
Publicado: (2020)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Evaluating the Risk of Inguinal Lymph Node Metastases before Surgery Using the Morphonode Predictive Model: A Prospective Diagnostic Study in Vulvar Cancer Patients
por: Fragomeni, Simona Maria, et al.
Publicado: (2023)

Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades
por: Simbolo, Michele, et al.
Publicado: (2021)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
por: Nero, Camilla, et al.
Publicado: (2022)

Current Roles of PET/CT in Thymic Epithelial Tumours: Which Evidences and Which Prospects? A Pictorial Review
por: Lococo, Filippo, et al.
Publicado: (2021)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Diagnosis of sarcoidosis in a patient with differentiated thyroid cancer and sudden rise of anti-thyroglobulin antibodies during follow-up
por: Vanessa, Feudo, et al.
Publicado: (2021)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT
por: Ingenerf, Maria, et al.
Publicado: (2023)

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry
por: Mizutani, Gou, et al.
Publicado: (2012)

PET Imaging in Recurrent Medullary Thyroid Carcinoma
por: Treglia, Giorgio, et al.
Publicado: (2012)

The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study
por: Caldarella, Carmelo, et al.
Publicado: (2021)

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors
por: Wang, Ling, et al.
Publicado: (2013)

Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer
por: Mori, Hiroshi, et al.
Publicado: (2018)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix
por: Saponjski, Jelena, et al.
Publicado: (2020)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
por: Wiesli, Peter, et al.
Publicado: (2019)

Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms
por: Inaba, Yoshitaka, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India
por: Sharma, Punit, et al.
Publicado: (2014)

Neuroendocrine neoplasms of the esophagus and stomach
por: Mastracci, Luca, et al.
Publicado: (2021)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_665of786cd01h5f4d6sda85ch5